-
1.发明申请公开(公告)号：US20190047977A1
公开(公告)日：2019-02-14
申请号：US15948821
申请日：2018-04-09
IPC分类号： C07D327/06 , C07D319/16 , C07D311/02 , C07D311/04 , C07D263/58 , C07D235/26 , C07D215/06 , C07D307/79 , C07D211/72 , C07D263/38 , C07D233/70 , C07D319/18 , C07D317/62 , C07D317/46 , C07D317/50
摘要： Certain compounds, or pharmaceutically acceptable salts or prodrugs thereof, are provided herein. Also provided are pharmaceutical compositions comprising at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of KMO activity are described, which comprise administering to such patients an amount of at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein effective to reduce signs or symptoms of the disease or disorder are disclosed. These diseases include neurodegenerative disorders such as Huntington's disease. Also described are methods of treatment include administering at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein as a single active agent or administering at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein in combination with one or more other therapeutic agents. Also provided are methods for screening compounds capable of inhibiting KMO activity.
-
2.发明申请公开(公告)号：US20180222838A1
公开(公告)日：2018-08-09
申请号：US15813001
申请日：2017-11-14
发明人： Leticia M. Toledo-Sherman , Celia Dominguez , Michael Prime , William Leonard Mitchell , Peter Johnson , Naomi Went
IPC分类号： C07C62/38 , C07H15/20 , C07D203/10 , C07C69/757 , C07D307/80 , C07D307/54 , C07D305/08 , C07D305/06 , C07D295/155 , C07D207/337 , C07D271/07 , C07D207/08 , C07C235/82 , C07D263/58 , C07D203/08 , C07D257/04 , C07C229/48 , C07C229/46 , C07C229/22 , C07C323/62 , C07D413/10 , C07D413/08 , C07C317/44 , C07D405/12 , C07D405/10 , C07D405/08 , C07D403/10 , C07D235/26 , C07D233/64 , C07D319/18 , C07D317/60 , C07D317/46 , C07D311/58 , C07D215/18 , C07D309/10 , C07D307/94 , C07D307/79 , C07D413/12
摘要： Certain compounds, or pharmaceutically acceptable salts or prodrugs thereof, are provided herein. Also provided are pharmaceutical compositions comprising at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of KMO activity are described, which comprise administering to such patients an amount of at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein effective to reduce signs or symptoms of the disease or disorder are disclosed. These diseases include neurodegenerative disorders such as Huntington's disease. Also described are methods of treatment include administering at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein as a single active agent or administering at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein in combination with one or more other therapeutic agents. Also provided are methods for screening compounds capable of inhibiting KMO activity.
-
3.发明授权公开(公告)号：US09938252B2
公开(公告)日：2018-04-10
申请号：US14392307
申请日：2014-09-23
IPC分类号： C07D327/06 , C07D215/06 , C07D235/26 , C07D263/58 , C07D307/79 , C07D311/04 , C07D317/50 , C07D311/02 , C07D317/46 , C07D317/62 , C07D319/18 , C07D233/70 , C07D263/38 , C07D211/72 , C07D319/16
CPC分类号： C07D327/06 , C07D211/72 , C07D215/06 , C07D233/70 , C07D235/26 , C07D263/38 , C07D263/58 , C07D307/79 , C07D311/02 , C07D311/04 , C07D317/46 , C07D317/50 , C07D317/62 , C07D319/16 , C07D319/18
摘要： Certain compounds, or pharmaceutically acceptable salts or prodrugs thereof, are provided herein. Also provided are pharmaceutical compositions comprising at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of KMO activity are described; which comprise administering to such patients an amount of at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein effective to reduce signs or symptoms of the disease or disorder are disclosed. These diseases include neurodegenerative disorders such as Huntington's disease. Also described are methods of treatment include administering at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein as a single active agent or administering at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein in combination with one or more other therapeutic agents. Also provided are methods for screening compounds capable of inhibiting KMO activity.
-
公开(公告)号：US09649310B2
公开(公告)日：2017-05-16
申请号：US15042964
申请日：2016-02-12
发明人： Celia Dominguez , Leticia M. Toledo-Sherman , Stephen Martin Courtney , Michael Prime , William Mitchell , Christopher John Brown , Paula C. De Aguiar Pena , Peter Johnson
IPC分类号： A61K31/506 , A61K31/505 , A61K31/5377 , A61K31/513
CPC分类号： A61K31/506 , A61K31/505 , A61K31/513 , A61K31/5377 , C07D239/26 , C07D239/28 , C07D239/42 , C07D401/04 , C07D403/04 , C07D413/04 , C07D413/14 , C07D417/04 , C07D491/044 , C07D491/048 , C07D491/052
摘要： Certain chemical entities are provided herein. Also provided are pharmaceutical compositions comprising at least one chemical entity and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of KMO activity are described, which comprise administering to such patients an amount of at least one chemical entity effective to reduce signs or symptoms of the disease or disorder are disclosed. These diseases include neurodegenerative disorders such as Huntington's disease. Also described are methods of treatment include administering at least one chemical entity as a single active agent or administering at least one chemical entity in combination with one or more other therapeutic agents. Also provided are methods for screening compounds capable of inhibiting KMO activity.
-
5.发明申请KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF 有权吉非烯-3-MONOOXYGENASE抑制剂，药物组合物及其使用方法公开(公告)号：US20160272611A1
公开(公告)日：2016-09-22
申请号：US14392307
申请日：2014-09-23
IPC分类号： C07D327/06 , C07D263/58 , C07D235/26 , C07D307/79 , C07D317/50 , C07D215/06 , C07D311/04 , C07D319/16
CPC分类号： C07D327/06 , C07D211/72 , C07D215/06 , C07D233/70 , C07D235/26 , C07D263/38 , C07D263/58 , C07D307/79 , C07D311/02 , C07D311/04 , C07D317/46 , C07D317/50 , C07D317/62 , C07D319/16 , C07D319/18
摘要： Certain compounds, or pharmaceutically acceptable salts or prodrugs thereof, are provided herein. Also provided are pharmaceutical compositions comprising at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of KMO activity are described; which comprise administering to such patients an amount of at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein effective to reduce signs or symptoms of the disease or disorder are disclosed. These diseases include neurodegenerative disorders such as Huntington's disease. Also described are methods of treatment include administering at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein as a single active agent or administering at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein in combination with one or more other therapeutic agents. Also provided are methods for screening compounds capable of inhibiting KMO activity.
摘要翻译： 本文提供了某些化合物或其药学上可接受的盐或前药。 还提供了包含本文所述的至少一种化合物或其药学上可接受的盐或前药和一种或多种药学上可接受的载体的药物组合物。 描述了治疗患有某些对KMO活性抑制作用的疾病和病症的患者的方法; 其包括向这些患者施用一定数量的有效减少疾病或病症的体征或症状的至少一种本文所述的化合物或其药学上可接受的盐或前药。 这些疾病包括神经变性疾病如亨廷顿氏病。 还描述了治疗方法，包括将本文所述的至少一种化合物或其药学上可接受的盐或前药作为单一活性剂施用或施用本文所述的至少一种化合物或其药学上可接受的盐或前药， 更多其他治疗剂。 还提供了用于筛选能够抑制KMO活性的化合物的方法。
-
6.发明申请公开(公告)号：US20160257674A1
公开(公告)日：2016-09-08
申请号：US14392304
申请日：2014-09-23
IPC分类号： C07D413/12 , C07D277/64 , C07D217/02 , C07D239/74 , C07D237/28 , C07D241/42 , C07D263/56 , C07D235/08 , C07D209/08 , C07D231/56 , C07D261/20 , C07D407/12 , C07D333/28 , C07D333/10 , C07D277/24 , C07D307/79
CPC分类号： C07D413/12 , C07D209/08 , C07D213/46 , C07D215/18 , C07D217/02 , C07D231/56 , C07D235/08 , C07D237/28 , C07D239/74 , C07D241/42 , C07D261/20 , C07D263/56 , C07D277/24 , C07D277/64 , C07D307/79 , C07D319/18 , C07D333/06 , C07D333/10 , C07D333/28 , C07D407/12
摘要： Certain compounds, or pharmaceutically acceptable salts or prodrugs thereof, are provided herein. Also provided are pharmaceutical compositions comprising at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of KMO activity are described, which comprise administering to such patients an amount of at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein effective to reduce signs or symptoms of the disease or disorder are disclosed. These diseases include neurodegenerative disorders such as Huntington's disease. Also described are methods of treatment include administering at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein as a single active agent or administering at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein in combination with one or more other therapeutic agents. Also provided are methods for screening compounds capable of inhibiting KMO activity.
-
7.发明授权公开(公告)号：US10442782B2
公开(公告)日：2019-10-15
申请号：US15813001
申请日：2017-11-14
发明人： Leticia M. Toledo-Sherman , Celia Dominguez , Michael Prime , William Leonard Mitchell , Peter Johnson , Naomi Went
IPC分类号： C07D311/20 , C07D307/79 , C07D263/58 , C07D235/26 , C07D319/18 , C07D317/46 , C07D215/18 , C07C62/38 , C07D307/94 , C07D309/10 , C07D311/58 , C07D317/60 , C07D233/64 , C07D403/10 , C07D405/08 , C07D405/10 , C07D405/12 , C07C317/44 , C07D413/08 , C07D413/10 , C07C323/62 , C07C229/22 , C07C229/46 , C07C229/48 , C07D257/04 , C07D203/08 , C07C235/82 , C07D207/08 , C07D271/07 , C07D207/337 , C07D295/155 , C07D305/06 , C07D305/08 , C07D307/54 , C07D307/80 , C07C69/757 , C07D203/10 , C07D413/12 , C07H15/20
摘要： Certain compounds, or pharmaceutically acceptable salts or prodrugs thereof, are provided herein. Also provided are pharmaceutical compositions comprising at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of KMO activity are described, which comprise administering to such patients an amount of at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein effective to reduce signs or symptoms of the disease or disorder are disclosed. These diseases include neurodegenerative disorders such as Huntington's disease. Also described are methods of treatment include administering at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein as a single active agent or administering at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein in combination with one or more other therapeutic agents. Also provided are methods for screening compounds capable of inhibiting KMO activity.
-
8.发明申请公开(公告)号：US20180215745A1
公开(公告)日：2018-08-02
申请号：US15851434
申请日：2017-12-21
IPC分类号： C07D413/12 , C07D231/56 , C07D215/18 , C07D333/06 , C07D241/42 , C07D277/24 , C07D277/64 , C07D213/46 , C07D307/79 , C07D263/56 , C07D261/20 , C07D239/74 , C07D237/28 , C07D235/08 , C07D217/02 , C07D209/08 , C07D407/12 , C07D333/28 , C07D333/10 , C07D319/18
CPC分类号： C07D413/12 , A61K31/343 , A61K31/416 , A61K31/4184 , A61K31/423 , A61K31/428 , A61K31/47 , A61K31/502 , A61K31/517 , C07D209/08 , C07D213/46 , C07D215/18 , C07D217/02 , C07D231/56 , C07D235/08 , C07D237/28 , C07D239/74 , C07D241/42 , C07D261/20 , C07D263/56 , C07D277/24 , C07D277/64 , C07D307/79 , C07D319/18 , C07D333/06 , C07D333/10 , C07D333/28 , C07D407/12
摘要： Certain compounds, or pharmaceutically acceptable salts or prodrugs thereof, are provided herein. Also provided are pharmaceutical compositions comprising at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of KMO activity are described, which comprise administering to such patients an amount of at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein effective to reduce signs or symptoms of the disease or disorder are disclosed. These diseases include neurodegenerative disorders such as Huntington's disease. Also described are methods of treatment include administering at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein as a single active agent or administering at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein in combination with one or more other therapeutic agents. Also provided are methods for screening compounds capable of inhibiting KMO activity.
-
公开(公告)号：US20160361312A1
公开(公告)日：2016-12-15
申请号：US15042964
申请日：2016-02-12
发明人： Celia Dominguez , Leticia M. Toledo-Sherman , Stephen Martin Courtney , Michael Prime , William Mitchell , Christopher John Brown , Paula C. De Aguiar Pena , Peter Johnson
IPC分类号： A61K31/506 , A61K31/5377 , A61K31/513 , A61K31/505
CPC分类号： A61K31/506 , A61K31/505 , A61K31/513 , A61K31/5377 , C07D239/26 , C07D239/28 , C07D239/42 , C07D401/04 , C07D403/04 , C07D413/04 , C07D413/14 , C07D417/04 , C07D491/044 , C07D491/048 , C07D491/052
摘要： Certain chemical entities are provided herein. Also provided are pharmaceutical compositions comprising at least one chemical entity and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of KMO activity are described, which comprise administering to such patients an amount of at least one chemical entity effective to reduce signs or symptoms of the disease or disorder are disclosed. These diseases include neurodegenerative disorders such as Huntington's disease. Also described are methods of treatment include administering at least one chemical entity as a single active agent or administering at least one chemical entity in combination with one or more other therapeutic agents. Also provided are methods for screening compounds capable of inhibiting KMO activity.
-
10.发明申请KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF 有权吉非烯-3-MONOOXYGENASE抑制剂，药物组合物及其使用方法公开(公告)号：US20150057238A1
公开(公告)日：2015-02-26
申请号：US14390190
申请日：2013-03-13
发明人： Leticia M. Toledo-Sherman , Celia Dominguez , Michael Prime , William Leonard Mitchell , Peter Johnson , Naomi Went
IPC分类号： C07C69/757 , C07D257/04 , C07H15/20 , C07D413/12 , C07D307/94 , C07D307/79 , C07D405/12 , C07D271/07 , C07D203/10
CPC分类号： C07C62/38 , C07C69/757 , C07C229/22 , C07C229/46 , C07C229/48 , C07C235/82 , C07C317/44 , C07C323/62 , C07C2601/02 , C07C2602/50 , C07D203/08 , C07D203/10 , C07D207/08 , C07D207/337 , C07D215/18 , C07D233/64 , C07D235/26 , C07D257/04 , C07D263/58 , C07D271/07 , C07D295/155 , C07D305/06 , C07D305/08 , C07D307/54 , C07D307/79 , C07D307/80 , C07D307/94 , C07D309/10 , C07D311/58 , C07D317/46 , C07D317/60 , C07D319/18 , C07D403/10 , C07D405/08 , C07D405/10 , C07D405/12 , C07D413/08 , C07D413/10 , C07D413/12 , C07H15/20
摘要： Certain compounds, or pharmaceutically acceptable salts or prodrugs thereof, are provided herein. Also provided are pharmaceutical compositions comprising at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of KMO activity are described, which comprise administering to such patients an amount of at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein effective to reduce signs or symptoms of the disease or disorder are disclosed. These diseases include neurodegenerative disorders such as Huntington's disease. Also described are methods of treatment include administering at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein as a single active agent or administering at least one compound, or pharmaceutically acceptable salt or prodrug thereof, described herein in combination with one or more other therapeutic agents. Also provided are methods for screening compounds capable of inhibiting KMO activity.
摘要翻译： 本文提供了某些化合物或其药学上可接受的盐或前药。 还提供了包含本文所述的至少一种化合物或其药学上可接受的盐或前药和一种或多种药学上可接受的载体的药物组合物。 描述了治疗患有某些对KMO活性抑制作用的疾病和病症的患者的方法，其包括对此类患者施用至少一种有效减少体征或症状的至少一种化合物或其药学上可接受的盐或前药 的疾病或病症。 这些疾病包括神经变性疾病如亨廷顿氏病。 还描述了治疗方法，包括将本文所述的至少一种化合物或其药学上可接受的盐或前药作为单一活性剂施用或施用本文所述的至少一种化合物或其药学上可接受的盐或前药， 更多其他治疗剂。 还提供了用于筛选能够抑制KMO活性的化合物的方法。
-
-
-
-
-
-
-
-
-
搜索结果
13 条记录 (耗时 0.029 秒)
